Transcranial Ultrasonography for the Management of Patients With Mild TBI (TRUST)

December 8, 2023 updated by: University Hospital, Grenoble

Transcranial Ultrasonography for the Management of Patients With Mild Traumatic Brain Injury

The investigators hypothesize that patients with mild TBI and normal TCD can be safely discharged home immediately after the ED. The targeted population is the category of patients eligible for early discharge: 1) patients with mild lesions on the initial CT scan and a GCS 15 after CT scan completion and, 2) patients with no lesion on the initial cerebral CT scan with at least one of the following risk factors: GCS 14 after CT scan completion, persisting post-traumatic nausea/vomiting/headaches, concomitant alcoholic intoxication or patients treated with aspirin. The study will not include mild TBI patients who are not eligible for early discharge: patients with no possibility of home supervision, those with a GCS lower than 14 after the CT scan or those treated with anticoagulant/antiplatelet drugs other than aspirin. The investigators expect the TCD-based strategy to be non-inferior compared to the standard strategy according to French recommendations in terms of the 3-months neurological outcome. From a public health standpoint, the use of TCD as a triage tool may change current guidelines regarding mild TBI management.

Study Overview

Status

Recruiting

Detailed Description

Patients with mild traumatic brain injury (TBI) represent the vast majority of TBI patients admitted in the emergency department (ED). According to French recommendations, mild TBI patients with brain lesions on initial CT scan are directed to a standard ward, where neurologic monitoring consists of repeated CT scanning and clinical exams. Patients with no lesion on initial cerebral CT scan are also hospitalized 1) when their GCS after CT scan is lower than 15, 2) in case of persisting nausea, vomiting or headache, 3) in case of concomitant alcoholic intoxication and, 4) in case of on-going treatment with aspirin. This strategy induces significant hospital stay with potential morbidity, whereas neurologic worsening rarely occurs.

In this context, the implementation of a triage tool in the ED would be useful to screen patients at risk of early neurologic worsening. Hence, low risk patients may be discharged at home immediately after the ED. Transcranial Doppler (TCD) is a non-invasive technique that measures cerebral blood flow velocities in intracranial cerebral arteries. These velocities and a derivated parameter (pulsatility index, PI), estimate cerebral blood flow (CBF) and have become a standard of care to optimize CBF in after severe TBI. Only few studies report the use of TCD after mild TBI. In a single-center cohort of patients with mild-to-moderate TBI, TCD parameters measured at hospital admission accurately predicted early neurologic worsening. These encouraging results indicate that TCD, in combination with CT scan findings, could play a role in the management of patients with mild TBI.

The aim of this project is to determine whether a TCD-based strategy is non-inferior to the standard management in terms of the overall neurological outcome at 3 months after mild TBI with no/minor lesions detected on a cerebral CT scan.

Study Type

Interventional

Enrollment (Estimated)

984

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Bourg-en-Bresse, France
        • Withdrawn
        • CH Bourg-en-Bresse
      • Clermont-Ferrand, France
        • Recruiting
        • CHU Clermont-Ferrand
        • Principal Investigator:
          • Christophe PERRIER, MD
      • Grenoble, France
        • Recruiting
        • Chu Grenoble Alpes
        • Principal Investigator:
          • DAMIEN VIGLINO, MD
        • Sub-Investigator:
          • Maxime MAIGNAN, MD
      • Lille, France
        • Recruiting
        • CHRU Lille
        • Principal Investigator:
          • Delphine GARRIGUE, MD
      • Lyon, France
        • Recruiting
        • HCL - Edouard Herriot
        • Principal Investigator:
          • Karim TAZAROURTE, MD, PhD
      • Lyon, France
        • Not yet recruiting
        • HCL - Lyon Sud
        • Principal Investigator:
          • Marion DOUPLAT, MD
      • Marseille, France
        • Withdrawn
        • AP-HM Timone
      • Melun, France
        • Recruiting
        • CH Melun
        • Principal Investigator:
          • David SAPIR, MD
      • Montpellier, France
        • Not yet recruiting
        • CHRU Montpellier
        • Principal Investigator:
          • Mustapha SEBBANE, MD, PhD
      • Nantes, France
        • Recruiting
        • CHU Nantes
        • Principal Investigator:
          • Philippe PES, MD
      • Nîmes, France
        • Withdrawn
        • CHU Nimes
      • Paris, France
        • Recruiting
        • AP-HP Lariboisiere
        • Principal Investigator:
          • Anthony CHAUVIN, MD
      • Paris, France
        • Recruiting
        • AP-HP Pitié Salpetrière
        • Principal Investigator:
          • Martha Cancella de Abreu, MD, PhD
      • Paris, France
        • Not yet recruiting
        • AP-HP - Avicenne
        • Principal Investigator:
          • Aurélien GUENIN, MD
      • Poitiers, France
        • Recruiting
        • CHU Poitiers
        • Principal Investigator:
          • Jeremy GUENEZAN, MD
      • Saint Pierre, France, 97448
        • Recruiting
        • CHU Réunion
        • Principal Investigator:
          • Nathalia EBRAN, MD
        • Sub-Investigator:
          • ADRIEN VAGUE, MD
      • Saint-Denis, France, 97400
        • Recruiting
        • CHU Réunion
        • Principal Investigator:
          • Bertrand GUIHARD, MD
      • Toulouse, France
        • Recruiting
        • CHU Toulouse
        • Principal Investigator:
          • Charles Henri Houzé-Cerfon, MD
      • Monaco, Monaco
        • Recruiting
        • CH Monaco
        • Principal Investigator:
          • Yann-Erick CLAESSENS, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Mild TBI (GCS 13-15 on ED admission) with one of the following:
  • Patient with minor cerebral lesion on initial CT scan (TCDBII i.e. no midline shift, visible basal cisterns and haemorrhagic lesion < 25 cc) and GCS 15 after CT scan
  • OR * Patient with normal initial CT scan (TCDB I) with at least one risk factor :

    • GCS = 14 after CT scan
    • and/or alcoholic intoxication
    • and/or on-going treatment with aspirin
    • and /or persisting nausea, and/or vomiting and/or headaches
    • Early initial CT scan (< 4 hours after TBI)
  • Possibility of home supervision by a third-party
  • Affiliation to the French social security system
  • Patient have signed consent form
  • Possibility to perform a TCD within 8 hours
  • Stable hemodynamics: systolic blood pressure >90 mmHg, peripheral capillary oxygen saturation >92%, hemoglobin > 8 g/dl

Exclusion Criteria:

  • CT scan classified as TCDB III - VI
  • Penetrating head-trauma
  • Patient under mechanical ventilation
  • Patients treated with anticoagulants or anti-platelet therapy (except Aspirin)
  • Hospitalization required by post-traumatic extra-cranial lesion, intoxication (except alcoholic), pre-existing condition (including congenital hemostasis disorders) or social factors at the discretion of the physician.
  • Internal Carotid dissection
  • Post-traumatic lesion in the posterior cerebral fossa
  • Subject in exclusion period of another interventional study,
  • Pregnant women, breastfeeding women
  • Subject under administrative or judicial control, under protection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TCD Group
Transcranial Doppler within 8 hours of traumatic injury

In the Emergency Department (ED):

After the initial cerebral CT scan, the patient will be included in the study when he/she satisfies inclusion criteria. TCD will be performed within 8 hours of the brain injury.

If TCD is normal (FVd>25 cm/sec and PI <1.25), the patient will return home under third-party supervision. An advice sheet will be given to the patient according to the SFMU guidelines and another one will be sent to the general practitioner. If initial cerebral CT scan is performed early (< 4-6 hours after TBI), CT scan should not be controlled before patient discharge.

If the TCD is abnormal (FVd≤25 cm/sec or PI ≥ 1.25) the patient will be hospitalized. There is no recommendation regarding the type of hospitalization (ICU or standard ward).

No other diagnostic procedure is allowed in the ED (S-100 protein dosing is not allowed). All therapies recommended by the SFMU for mild TBI are allowed in this group.

No Intervention: CONTROL Group
Mild TBI management with SFMU recommandations

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Non-inferiority of a TCD-based strategy after a mild TBI to the standard management in terms of the overall neurological outcome
Time Frame: 3 months after TBI
GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.
3 months after TBI

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Effects of a TCD-based strategy after a mild TBI on the overall neurological outcome
Time Frame: 1 month after TBI
GOS-E will be dichotomized as good recovery (GOS-E 7 or 8) vs. disability (GOS-E 1 to 6). Evaluation is centralized and blinded.
1 month after TBI
Effects of a TCD-based strategy after a mild TBI on the quality of life
Time Frame: 1 months after TBI
Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L
1 months after TBI
Effects of a TCD-based strategy after a mild TBI on the quality of life
Time Frame: 3 months after TBI
Questionnaires QOLIBRI (Quality of life after TBI) and EQ-5D-5L
3 months after TBI
Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome
Time Frame: 1 month after TBI
Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI ("Rivermead positive" patients are patients with at least 3 symptoms rated ≥ 2)
1 month after TBI
Effects of a TCD-based strategy after a mild TBI on Post-concussive syndrome
Time Frame: 3 months after TBI
Rivermead Post-Concussion Symptoms questionnaire at 1 month and 3 months after TBI ("Rivermead positive" patients are patients with at least 3 symptoms rated ≥ 2)
3 months after TBI
Effects of a TCD-based strategy after a mild TBI on Morbidity after TBI
Time Frame: 1 months after TBI
Number of cerebral CT scans within the hospital stay, • Thromboembolic events or diagnosed nosocomial infections stay
1 months after TBI
Effects of a TCD-based strategy after a mild TBI on mortality after TBI
Time Frame: 3 months after TBI
Mortality within the first 3 months
3 months after TBI
Effects of a TCD-based strategy after a mild TBI on patient safety
Time Frame: 3 months after TBI
Number of patients with neurologic worsening within the first week after TBI.
3 months after TBI

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Pierre BOUZAT, MD, PhD, University Hospital, Grenoble

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2020

Primary Completion (Estimated)

May 1, 2025

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

June 14, 2019

First Submitted That Met QC Criteria

June 14, 2019

First Posted (Actual)

June 18, 2019

Study Record Updates

Last Update Posted (Estimated)

December 11, 2023

Last Update Submitted That Met QC Criteria

December 8, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Traumatic Brain Injury

Clinical Trials on Transcranial Doppler (TCD)

3
Subscribe